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Prenatal Sonographic Features of 22q11.2
Microdeletion Syndrome
Chih-Ping Chen1,2,3*, Shu-Chin Chien4,5
Fetuses with 22q11.2 microdeletions (del22q11.2) have variable clinical expressions.
Associated congenital anomalies include cardiac defects, abnormal facies, thymic hypoplasia
or aplasia, velopharyngeal insufficiency, cleft palate, hypocalcaemia due to parathyroid
aplasia or hypoplasia, and learning disability. Statistically, most cases are sporadic and only
about 8% are inherited. The microdeletion can be easily diagnosed with fluorescence 
in situ hybridization or molecular analysis of fetal cells, but there is lack of definite indica-
tions for the prenatal diagnosis of sporadic cases with del22q11.2. Currently, ultrasound
is viewed as a valuable tool in the detection of sporadic cases of del22q11.2 syndrome.
This article provides an overview of the prenatal sonographic features of del22q11.2 syn-
drome, including cardiovascular abnormalities, thymic hypoplasia or aplasia, intrauterine
growth restriction, urinary abnormalities, increased nuchal translucency thickness, and
abnormal amniotic fluid levels. Among these abnormalities, prenatal cardiac involvement
is a prominent feature, especially conotruncal cardiac defects. The additional visualization
of fetal thymus and detection of intrauterine growth restriction on obstetric ultrasound
can enhance the detection rate of del22q11.2. Prenatal testing for 22q11.2 deletion should
therefore be considered when a conotruncal cardiac defect accompanying other associ-
ated abnormalities are detected on prenatal ultrasound. Owing to the phenotypic diversity
of 22q11.2 microdeletion syndrome, increasing awareness and knowledge of fetal abnor-
malities on prenatal ultrasound will be helpful in the prenatal detection of del22q11.2.
Early diagnosis of fetuses with del22q11.2 could help obstetricians, surgeons, pediatric
cardiologists and geneticists in the decision-making process for prenatal, perinatal or
postnatal care.
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Introduction
Lack of expression of critical genes within chromo-
some 22q11.2 affects the normal development of the
heart, face, thymus, palate and parathyroid glands,
which may result in various clinical entities such as
DiGeorge syndrome, velocardiofacial syndrome, and
conotruncal anomaly face syndrome. DiGeorge syn-
drome is characterized by congenital cardiac defects,
T-cell immunodeficiency due to thymic absence or
hypoplasia, and hypocalcaemia due to parathyroid
aplasia or hypoplasia [1]. Velocardiofacial syndrome
manifests as cleft palate, cardiac defects, learning
disability, and typical facies [2,3]. Conotruncal anom-
aly face syndrome comprises congenital heart dis-
eases, a peculiar face with frequent appearance of
cleft palate or hypernasality [4]. Statistically, 35–90%
of DiGeorge syndrome patients and 80–100% of
velocardiofacial syndrome patients have this dele-
tion [2,5–8]. The spectrum of common abnormal-
ities associated with del22q11.2 has been grouped
by Wilson et al [9] under the acronym CATCH 22
for Cardiac defects, Abnormal facies, Thymic hy-
poplasia, Cleft palate, Hypocalcaemia and 22q11
microdeletion. The deleted size ranges from 1.5 to
3.0 Mb, but the phenotypic variability is reportedly
not related to the extent of the deletion [10].
The incidence of del22q11.2 is reported to 
be approximately 1 in 3,900 to 1 in 9,700 [9,
11–13]. Most affected cases occur sporadically, with
only 8% being inherited [14]. The diagnosis can be
accurately made by fluorescence in situ hybridiza-
tion and molecular genetic analysis of the deleted
region [7]. These methods are also feasible for diag-
nosis in fetal cells. The detection of fetuses with
del22q11.2 is mostly from selected cases with a
positive family history [7,15]. In sporadic cases, the
legitimate indications for early detection of affected
fetuses remains controversial. In the first case of pre-
natal diagnosis of sporadic 22q11 deletion, a cardiac
anomaly was reportedly seen on fetal echocardiog-
raphy [16]. Ultrasound is thought to be a valuable
tool in the early detection of affected fetuses owing
to the possible structural abnormalities seen in cases
with del22q11.2. Here, we review the associated
sonographic features in fetuses with del22q11.2 and
the prenatal sonographic findings including car-
diovascular abnormalities, thymic hypoplasia or apla-
sia, intrauterine growth restriction (IUGR), urinary
abnormalities, increased nuchal translucency thick-
ness (NT), and abnormal amniotic fluid levels. Early
diagnosis of fetuses with del22q11.2 is significantly
beneficial in determining the gestational course and
providing adequate postnatal surgical or medical
interventions.
Prenatal Sonographic Features
Prenatal sonographic markers suggestive of
del22q11.2 syndrome include type I markers of
fetal structural abnormalities in the cardiovascular
and urinary systems, thymic hypoplasia or aplasia,
IUGR, and type II soft markers of nonspecific and
transient fetal abnormalities such as increased NT
and abnormal amniotic fluid levels (Table). Other
structural malformations are uncommon, such as
cerebellar hypoplasia [17], spina bifida [18], hydro-
cephaly and mild ventriculomegaly [19], upper limb
malformations [9,20], club feet [21], esophageal
atresia [19,22], and congenital diaphragmatic her-
nia [19]. However, these associated malformations
are often detected in affected cases with underly-
ing cardiac defects. Interestingly, abnormal facies
and cleft palate are two major diagnostic criteria in
postnatal cases with del22q11.2; but dysmorphic
facies and cleft palate are not applicable to prena-
tal diagnosis, because they are relatively inaccessi-
ble to ultrasound survey in the fetal period [23].
Hence, there are only rare reports of fetuses with
del22q11 detected with facial anomalies on prena-
tal ultrasound. Among the soft markers, bilateral
echogenic intracardiac foci were noted in one fetus
with 22q11 microdeletion [24]. However, the possi-
ble association between echogenic intracardiac foci
and del22q11.2 has not yet been emphasized. The
authors recommended that targeted echocardiog-
raphy should be performed in cases with unusual
echogenic intracardiac foci to exclude an isolated
left ventricular echogenic focus [24].
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Type I Markers — Major Structural
Abnormalities
Cardiovascular abnormalities
Next to Down syndrome, del22q11.2 is the second
most frequent chromosomal anomaly in fetuses with
cardiac defects as well as aberrant karyotypes [7,25].
Cardiovascular abnormalities have been reported
in about 75–83% of cases with del22q11 [23,26].
In earlier reports, interruption of the aortic arch (IAA)
type B, truncus arteriosus and tetralogy of Fallot were
found to be the most common cardiac anomalies
in DiGeorge syndrome [27]. In velocardiofacial syn-
drome, tetralogy of Fallot, ventricular septal defects
and right aortic arch were found to be the most com-
mon [28], and all of these cardiac abnormalities were
commonly seen in conotruncal anomaly face syn-
drome [4]. The prevalence rates of 22q11.2 deletion
within conotruncal heart malformations may differ
in fetal, neonatal and pediatric cardiology series. In
a series of 17 nonsyndromic children with congenital
conotruncal heart defects, five (29.4%) were found
to have a 22q11 deletion [29]. Forty-eight percent of
infants with congenital conotruncal cardiac anom-
alies had the 22q11 microdeletion [30]. Boudjemline
et al [31] reported a prevalence of 20.7% for this
deletion in a large group of 261 fetuses with cono-
truncal anomalies. Among 76 fetuses with various
conotruncal anomalies, 10 fetuses (13.1%) had a
22q11.2 deletion and these abnormalities were IAA,
absent pulmonary valve syndrome, truncus arte-
riosus or tetralogy of Fallot [32]. Twenty-eight of 141
fetuses with malformations of the outflow tracts or
IAA had 22q11 microdeletion (19.8%), of which
IAA, common arterial trunk and absent pulmonary
valve were the most common [19]. Therefore, the
detection rate of fetuses with cardiac conotruncal
abnormalities and del22q11.2 is about 13–20%.
Currently, the reported common cardiovascular ab-
normalities in cases with del22q11.2 include IAA,
truncus arteriosus, tetralogy of Fallot, double outlet
right ventricle, atresia or stenosis of the pulmonary
valve, and ventricular septal defects [33,34]. Other
reported rare cardiac malformations in association
with del22q11.2 include atrial septal defects, trans-
position of the great arteries, tricuspid atresia, double
aortic arch, IAA type C [35], IAA type A, coarctation
of the aorta, right aortic arch [19], hypoplastic left
heart syndrome [36], and isomerism [37]. Among
these anomalies, conotruncal cardiac defects, rep-
resenting malformations of the great vessels, are the
most prominent features [35,38,39].
Thymic hypoplasia or aplasia
Thymic hypoplasia or aplasia is one of the diagnostic
criteria in patients with del22q11.2, and assessment
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Table. Prenatal sonographic features of del22q11.2
Type I markers — major structural anomalies
Cardiac abnormalities
Interrupted aortic arch type B, truncus arteriosus, tetralogy of Fallot, double outlet right ventricle, atresia or 
stenosis of the pulmonary valve, ventricular septal defects
Rare malformations: atrial septal defects, transposition of the great arteries, tricuspid atresia, double aortic arch, 
interrupted aortic arch type C and type A, coarctation of the aorta, right aortic arch, hypoplastic left heart 
syndrome, and isomerism.
Absent or hypoplastic thymus
Intrauterine growth restriction
Urinary abnormalities
Renal agenesis, multicystic kidneys, and obstructive abnormalities such as hydroureter and hydronephrosis
Type II markers — soft markers
Increased nuchal translucency thickness
Abnormal amniotic fluid levels
of the fetal thymic status is considered a marker in
the early detection of del22q11.2 [32]. Clinically,
the developed fetal thymus can easily be visualized
after 15 weeks of gestation with increased resolu-
tion of ultrasound equipment when using a high-
frequency transducer [40–42]. Fetal thymus in front
of great vessels is best evaluated in the “three-vessel”
view on obstetric ultrasound, which is often used
to assess fetal conotruncal and aortic arch abnor-
malities. In fetuses with cardiomegaly resulting in
compression of the lungs and thymus, ultrasound
evaluation of fetal thymus is then of limited value
[43]. In one report, 11 of 76 fetuses with conotrun-
cal anomalies had additional thymic hypoplasia or
aplasia. Nine of these 11 fetuses were confirmed
with del22q11.2, two cases were false positive and
only one fetus with del22q11.2 had a normal-sized
thymus. The diagnostic sensitivity was 90% and the
specificity was 98.5% [32]. The authors concluded
that diagnosis of fetuses with del22q11 is more spe-
cific and sensitive by direct visualization of the fetal
thymus on ultrasound than by subtype of cardiac
anomaly alone [32]. This study group also observed
that the combination of thymic aplasia and cardiac
conotruncal abnormalities could be very specific
for this chromosomal deletion [24].
IUGR
IUGR is defined as less than the 10th centile of pre-
dicted fetal weight for gestational age. It has been
reported in fetuses with del22q11.2 in the second or
third trimesters [19,44]. IUGR seems to be associated
with a poor prognosis, leading to either intrauterine
fetal deaths or postnatal deaths [19]. It was noted
that the combination of IUGR, additional aortic arch
anomalies and thymic hypoplasia or aplasia could
be used to detect fetuses with del22q11.2 and had
a sensitivity of 90% and a specificity of 100% [19].
It was reported that 22q11.2 deletion syndrome
should be considered in fetuses with congenital
cardiac malformations and IUGR [44].
Urinary abnormalities
Urinary abnormalities reported in cases with del-
22q11.2 include renal agenesis, multicystic kidneys,
and obstructive abnormalities such as hydroureter
and hydronephrosis. Devriendt et al [45] reported
that four of 39 patients (10.2%) with del22q11.2 had
a renal abnormality, including bilateral obstructive
megaureter in one case, unilateral renal agenesis in
two cases, and unilateral multicystic kidney in one
case. The European CATCH 22 Consortium Database
revealed that 49 of 136 patients with del22q11.2
had renal abnormalities such as absent kidneys, mul-
ticystic kidneys, obstructive abnormalities, and vesi-
coureteric reflux (personal communication). Three
fetuses with 22q11 deletions had urinary abnor-
malities including a right hydroureter and hydro-
nephrosis with a ureterocele bulging into the bladder
lumen, bilateral multicystic kidneys with associated
oligohydramnios, and a left multicystic kidney with
right renal agenesis and associated oligohydramnios
[46]. Despite the fact that structural abnormalities
in the urinary system may occur with del22q11.2,
the cause of these renal abnormalities remains to be
explained [47]. It is not recommended that fetuses
with an isolated renal anomaly be routinely tested
for the 22q11 deletion [46].
Type II Markers — Soft Markers
Increased NT
The term “fetal NT” refers to the sonographic finding
of subcutaneous fluid accumulation behind the fetal
neck. Previous studies have provided evidence that
increased fetal NT is significantly associated with
chromosomal abnormalities, congenital cardiac de-
fects [48,49], pulmonary defects, skeletal dysplasia,
congenital infections, metabolic diseases, and hema-
tologic disorders [50]. The outcome of thickened
nuchal fold in affected fetuses with conotruncal car-
diac anomalies as well as del22q11.2 might result
in either spontaneous regression [51], or hydrops
fetalis and subsequent fetal death [24]. The first case
of CATCH 22 in association with increased NT in
the first trimester was described in 1998 [51]. The
authors reported on a fetus with a 5.6-mm NT, cho-
roid plexus cysts and an intracardiac echogenic focus
at 12+5 weeks of gestation, but no fetal abnormality
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was detected on ultrasound at 22 weeks. However,
right renal agenesis, conotruncal cardiac defects,
hypocalcemia and the presence of del22q11.2 were
disclosed postnatally. In a large study of 398 fetuses
with increased NT and normal karyotype, fetal echo-
cardiography demonstrated 29 fetuses as having a
major cardiac defect, of which four fetuses (13%)
had a 22q11.2 microdeletion [52]. In another study
of 80 chorionic villus samples from fetuses with
excess nuchal translucency and normal karyotype,
no 22q11 deletions were detected [53]. Based on the
literature reports, it is not recommended to test for
22q11.2 microdeletion in all fetuses with increased
NT unless fetal cardiac defects, especially conotruncal
anomalies, are detected on a detailed echocardio-
graphy in later gestation [24,53,54].
Abnormal amniotic fluid levels
(polyhydramnios and oligohydramnios)
Polyhydramnios had been reported in eight out of
52 patients with del22q11.2 (16%), the severity and
the time of onset of polyhydramnios were variable
[55]. Five of these eight patients had a significant
structural anomaly, including cardiac defects, hydro-
nephrosis and a single umbilical artery. The presence
of polyhydramnios was associated with decreased
swallowing of amniotic fluid due to hypotonia and
poor sucking in these cases with del22q11.2 or the
result of velopharyngeal insufficiency or cleft palate
[56]. Another rare anomaly of esophageal atresia
associated with del22q11.2 might be associated
with polyhydramnios in later pregnancy [22]. Oli-
gohydramnios was also detected in fetuses with
del22q11.2 due to renal malformations [46]. A stan-
dard chromosome analysis and fluorescence in situ
hybridization for del22q11.2 should be performed in
otherwise unexplained polyhydramnios or oligohy-
dramnios associated with malformations frequently
found in CATCH.
Summary
Del22q11.2 is a frequent disorder. However, it is dif-
ficult to predict the long-term prognosis of these
cases because of highly variable phenotypes demon-
strated in familial cases [57]. For most sporadic cases,
there is a lack of definite indications for the prenatal
diagnosis of del22q11.2. At present, sonographi-
cally detected fetal abnormalities associated with
del22q11.2 might be the main strategy to identify
sporadic cases. Prenatal sonographic features in rela-
tion to del22q11.2 include cardiovascular abnor-
malities, thymic hypoplasia or aplasia, IUGR, urinary
abnormalities, increased NT, and abnormal amni-
otic fluid levels. Among these anomalies, prenatal
cardiac involvement is a prominent feature, espe-
cially conotruncal cardiac defects. In addition to the
fetal cardiac defects, the direct visualization of fetal
thymus and detection of IUGR can enhance the
detection rate of del22q11.2. Therefore, prenatal
testing for del22q11.2 should be offered when ultra-
sound findings of conotruncal cardiac defects as well
as other abnormalities frequently found in CATCH
22 with a normal karyotype are detected. In our
opinion, increasing awareness and knowledge of the
fetal status on prenatal ultrasound will be consider-
ably useful for the prenatal detection of del22q11.2.
Early diagnosis of fetuses with del22q11.2 could help
clinicians to make decisions on the mode of deliv-
ery and postnatal surgery, the prevention of possi-
ble neonatal complications, and the detection of
affected family members.
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